Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development: IUPHAR Review 29
S P H Alexander, Jane F Armstrong, Anthony P. Davenport, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 21, pp. 4942-4966
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Azithromycin in the treatment of COVID-19: a review
Daniel Echeverría-Esnal, Clara Martín‐Ontiyuelo, María Eugenia Navarrete-Rouco, et al.
Expert Review of Anti-infective Therapy (2020) Vol. 19, Iss. 2, pp. 147-163
Open Access | Times Cited: 234
Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology
Simon J. Cleary, Simon C. Pitchford, Richard T. Amison, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 21, pp. 4851-4865
Open Access | Times Cited: 181
Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19
Aakriti Gupta, Mahesh V. Madhavan, Timothy J. Poterucha, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 177
The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials
Simon D Harding, Jane F Armstrong, Elena Faccenda, et al.
Nucleic Acids Research (2021) Vol. 50, Iss. D1, pp. D1282-D1294
Open Access | Times Cited: 136
Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
Julian Breidenbach, Carina Lemke, Thanigaimalai Pillaiyar, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 18, pp. 10423-10429
Open Access | Times Cited: 131
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19
Carolina Q. Sacramento, Natália Fintelman-Rodrigues, Jairo R. Temerozo, et al.
Journal of Antimicrobial Chemotherapy (2021) Vol. 76, Iss. 7, pp. 1874-1885
Open Access | Times Cited: 87
Drug targets for COVID-19 therapeutics: Ongoing global efforts
Ambrish Saxena
Journal of Biosciences (2020) Vol. 45, Iss. 1
Open Access | Times Cited: 80
In Vitro and In Vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic
Rafael Borges Rosa, Willyenne Marília Dantas, Jéssica Catarine Frutuoso do Nascimento, et al.
Viruses (2021) Vol. 13, Iss. 3, pp. 379-379
Open Access | Times Cited: 69
Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Gomaa Mostafa‐Hedeab, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 56
Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19
George Abraham, Rhoda E. Kuc, Magnus Althage, et al.
Journal of Molecular and Cellular Cardiology (2022) Vol. 167, pp. 92-96
Open Access | Times Cited: 41
Potential for Early Noninvasive COVID-19 Detection Using Electronic-Nose Technologies and Disease-Specific VOC Metabolic Biomarkers
A. D. Wilson, Lisa Beth Forse
Sensors (2023) Vol. 23, Iss. 6, pp. 2887-2887
Open Access | Times Cited: 22
Is the COVID‐19 thrombotic catastrophe complement‐connected?
Edward M. Conway, Edward L.G. Pryzdial
Journal of Thrombosis and Haemostasis (2020) Vol. 18, Iss. 11, pp. 2812-2822
Open Access | Times Cited: 64
Exploring the role of triazole functionalized heteroatom co-doped carbon quantum dots against human coronaviruses
Piyush Garg, Sujata Sangam, Dakshi Kochhar, et al.
Nano Today (2020) Vol. 35, pp. 101001-101001
Open Access | Times Cited: 64
Crystal Structure of Non-Structural Protein 10 from Severe Acute Respiratory Syndrome Coronavirus-2
Annika Rogstam, Maria Nyblom, Signe Christensen, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7375-7375
Open Access | Times Cited: 62
Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis
Rajith K. R. Rajoli, Henry Pertinez, Usman Arshad, et al.
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 4, pp. 2078-2088
Open Access | Times Cited: 57
Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity
Ying Li Weng, Shiv Rakesh Naik, Nadia Dingelstad, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 52
Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein
Giuseppe Deganutti, Filippo Prischi, Christopher A. Reynolds
Journal of Computer-Aided Molecular Design (2020) Vol. 35, Iss. 2, pp. 195-207
Open Access | Times Cited: 51
Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication
Yi Zhang, Liang Tang
Journal of Proteome Research (2020) Vol. 20, Iss. 1, pp. 49-59
Closed Access | Times Cited: 42
Drug repurposing against SARS-CoV-2 using computational approaches
Sumit Kumar, Svitlana Kovalenko, Shakshi Bhardwaj, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 7, pp. 2015-2027
Open Access | Times Cited: 23
Epidemiological Analysis of a K. pneumoniae NDM Outbreak in a Temporary Ward for Patients with Primary COVID-19 Infection
Agata Pruss, Klaudia Miładowska, Helena Masiuk, et al.
Microbiology Research (2025) Vol. 16, Iss. 1, pp. 17-17
Open Access
A lesson from a saboteur: High‐MW kininogen impact in coronavirus‐induced disease 2019
Chiara Colarusso, Michela Terlizzi, Aldo Pinto, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 21, pp. 4866-4872
Open Access | Times Cited: 37
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics
Dmitry Tworowski, Alessandro Gorohovski, Sumit Mukherjee, et al.
Nucleic Acids Research (2020) Vol. 49, Iss. D1, pp. D1113-D1121
Open Access | Times Cited: 36
The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2
Carolina Q. Sacramento, Natália Fintelman-Rodrigues, Jairo R. Temerozo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access | Times Cited: 35
Exploration of sex-specific and age-dependent COVID-19 fatality rate in Bangladesh population
Md. Abdul Alim Al‐Bari, Showna Hossain, Md. Kudrat‐E‐Zahan
World Journal of Radiology (2021) Vol. 13, Iss. 1, pp. 1-18
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top